PLMA_1170x120_7-2-21

Synjardy

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

FDA approves Boehringer Ingelheim, Eli Lilly’s Synjardy

RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. have received approval from the Food and Drug Administration for Synjardy tablets, a medication for type 2 diabetes. The companies said Thursday that Synjardy (empagliflozin and metformin hydrochloride) marks their third product containing empagliflozin to be approved by the FDA, following